Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngen Biotech CoROCO:8279 -0.13%90 Debt-to-EBITDA is 0.59 as of Jun. 2026, which is 39% below its 10-year median of 0.97. GuruFocus rates ROCO:8279 with a GF Score™ of 90/100 and a GF Value™ of NT$133.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 304 Biotechnology companies, Syngen Biotech Co ranks better than 60.2% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Syngen Biotech Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:8279'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.39 Med: 0.97 Max: 1.61
Current: 0.68
During the past 13 years, the highest Debt-to-EBITDA Ratio of Syngen Biotech Co was 1.61. The lowest was 0.39. And the median was 0.97.
ROCO:8279's Debt-to-EBITDA is ranked better than 60.2% of 304
companies
in the Biotechnology industry
Industry Median: 1.215
vs ROCO:8279: 0.68
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Syngen Biotech Co Debt-to-EBITDA Related Terms
Syngen Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Syngen Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Syngen Biotech Co (ROCO:8279) has a Debt-to-EBITDA of 0.59 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syngen Biotech Co. This is 39% below median its historical median of 0.97. Over the past decade, Syngen Biotech Co's Debt-to-EBITDA has ranged from 0.39 to 1.61. According to the industry distribution chart, Syngen Biotech Co ranks #121 out of 304 companies in the Biotechnology industry, placing it in the top 39.8%.
Is Syngen Biotech Co's Debt-to-EBITDA too high?
Syngen Biotech Co's current Debt-to-EBITDA of 0.59 is 39% below median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.61. The Biotechnology industry median Debt-to-EBITDA is 1.22. Syngen Biotech Co's value of 0.59 is 51.4% below this industry median. Based on the distribution chart, Syngen Biotech Co ranks #121 out of 304 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syngen Biotech Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #121 out of 304 companies for Debt-to-EBITDA. This puts Syngen Biotech Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.22. Syngen Biotech Co's value of 0.59 is 51.4% below this benchmark. Historically, Syngen Biotech Co's own Debt-to-EBITDA has ranged from 0.39 to 1.61 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 1.22, Syngen Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngen Biotech Co's current Debt-to-EBITDA of 0.59 is 51.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syngen Biotech Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngen Biotech Co's current Debt-to-EBITDA is 0.59, which is 39% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$133.31, compared to a current price of NT$78.70 — trading 41% below its estimated fair value. The current Debt-to-EBITDA is 0.59, which is 39% below median its 10-year median of 0.97 and 51.4% below the Biotechnology industry median of 1.22. Syngen Biotech Co's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Debt-to-EBITDA is 0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$78.70 is trading 41% below its estimated GF Value™ of NT$133.31.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
Debt-to-EBITDA: 0.59 (39% below median its 10-year median of 0.97)
GF Value™: NT$133.31 vs. price of NT$78.70 (41% below fair value)
Industry Position: 51.4% below the Biotechnology median (#121 of 304)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
90GF Score
Get the complete analysis for ROCO:8279
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
